Alcon introduced its new Phakic IntraOcular Lens at this week’s European Society of Cataract and Refractive Surgery in Berlin.  This lens is an anterior chamber IOL that sits in front of the iris.  It is used to treat nearsightedness.  It offers the advantage of being a reversible procedure and having the ability to treat many patients who have been deemed poor LASIK candidates.  It can also treat patients who require stronger prescriptions than can be treated with LASIK.  This lens is only available overseas at this time as it is awaiting FDA approval.


The Acrysof Phakic Lens joins two other Phakic IOLs that already have FDA approval:

  • Verisyse® Phakic IOL sits in the front of the eye and is attached to the iris.


EyeCare 20/20 has been implanting both Phakic IOLs since their FDA approval several years ago.  Results have been excellent, with generally an improvement of vision as compared to vision with glasses before the surgery.  With the impending FDA approval of the new Acrysof, we anticipate adding this new lens to our refractive strategies.

The information presented on this Site and Blog and any related links is provided for educational, informational, and entertainment purposes only. Nothing contained in this Site is intended to create a physician-patient relationship, to replace the services of a licensed, trained physician or health professional or to be a substitute for medical advice of a physician or trained health professional licensed in your state. You must never consider any of the information presented here as a substitute for consulting with your physician or health care provider for any medical conditions or concerns. Any information presented here is general information, is not medical advice, nor is it intended as advice for your personal situation. Please consult with your physician or health care provider if you have concerns about your health or suspect that you might have a problem.